Ed is a co-founder of KalVista and joined as Chief Scientific Officer in 2016. Previously, Dr. Feener was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center. He has 30 years of research experience in vascular biology and diabetic complications. His laboratory has performed pioneering research on the kallikrein kinin system and was first to identify plasma kallikrein as a potential therapeutic target for diabetic macular edema. Ed has published over 80 scientific articles and has served on multiple national and international scientific research review committees.
Ed received his PhD in Biochemistry from Boston University and completed postdoctoral training at the Joslin Diabetes Center and Harvard Medical School.
